Received Sep 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | IM |
she developed a rash in the abdomen and around the broad-line; This spontaneous case was reported by a consumer and describes the occurrence of RASH (she developed a rash in the abdomen and around the broad-line) in a female patient of an unknown age who received mRNA-1273.251 (Spikevax LP.8.1 PFS) for COVID-19 prophylaxis. No Medical History information was reported. On 04-Sep-2025, the patient received dose of mRNA-1273.251 (Spikevax LP.8.1 PFS) (Intramuscular use) 1 dosage form. On 06-Sep-2025, after starting mRNA-1273.251 (Spikevax LP.8.1 PFS), the patient experienced RASH (she developed a rash in the abdomen and around the broad-line). On 07-Sep-2025, RASH (she developed a rash in the abdomen and around the broad-line) had resolved. No concomitant medication was reported. The patient was vaccinated with Spikevax on 4-Sep-2025 and on 6-Sep-2025, she developed a rash in the abdomen and around the broad-line. The rash disappeared on the 7-Sep-2025. The patient did not experience any additional symptoms or events. Reporter causality was not reported. No treatment medication was reported. Most recent FOLLOW-UP information incorporated above includes: On 09-Sep-2025: Live non-significant follow-up received with narrative and reference ID added